NeurAxis Grew 150% and the Market Priced the Stock-Comp Charge Instead
Two national payers, 147 million covered lives, a 38% prior-auth rate — and a $4.3 million non-cash RSU exchange that buried the operating story
NRXS · Earnings Call · 2026-11-09
The best quarter in company history, filtered through accounting noise
NeurAxis printed $2 million of revenue in fiscal Q3 2026 — up roughly 150% year over year, the strongest quarter in the company's history, the ninth consecutive quarter of double-digit growth, and the second straight above 100%. Gross margin expanded 330 basis points to 86.6%. On the operating story, this was the quarter the reimbursement thesis finally started showing up in the P&L rather than in a slide deck.
And yet the quarter's keyword surface is dominated by accounting debris. stock compensation is the single highest-momentum term in the company's curated set, trailed by onetime nonrecurring, operating loss and canceled stock options. That is a tell. Total operating expenses of $8.3 million rose 200% year over year — but strip out $4.3 million from the issuance of restricted stock units exchanged for canceled options, and opex was $4 million, up 45%. The GAAP net loss of $6.5 million looks like a blowout; the adjusted figure of $2.2 million is only 6% worse than a year ago while revenue more than doubled. The gap between the two is the entire story of why this report reads worse than the business did.
The last filed 10-Q (period ending May 31) shows a company whose top line had already inflected while its loss line stayed pinned: revenue of $2 million, up 80% year over year and 66% sequentially in the June quarter. The September quarter the call just described doubles down on that shape.
Coverage headline versus coverage reality
Management's marquee claim is access. With the addition of two large national payers in the past 45 days, Brian Carrico said the footprint now includes “approximately 147 million covered lives” — Brian Carrico, Chief Executive Officer · 2026-11-09. That is genuine progress on the payer coverage axis that has governed every call for the past two years.
But the more interesting disclosure was the one nobody asked for: the CEO volunteered the state-level coverage distribution. Four states are at 70%–76% commercial coverage, four at 60%–69%, five at 50%–59%, and seven at 40%–49%. Why does the ladder matter? Because on the prior call, asked what percentage of covered lives a children's hospital needs before it will commit to a real program, Carrico answered in one word: “70%.” — Brian Carrico, CEO · 2026-08-11 He has now told investors, with his own KPIs, that only four states clear his own commitment bar. The 147-million-lives number is a national statistic; the 70% threshold is a hospital-by-hospital decision. The gap between them is why clinic capacity — not coverage — remains the binding constraint.
The second implementation wrinkle is worth flagging because it is the rare case of management narrating a problem in real time rather than a quarter later: “one of those payers is one I mentioned that we have not seen any impact because there was a miscommunication between in the policy and their prior authorization” — Brian Carrico, Chief Executive Officer · 2026-11-09 — the payer was authorizing one device instead of the full four-device course. A national contract that cannot be executed at the pharmacy-counter level of detail is not yet revenue.
The KPI that actually captures this is prior authorization: 12% through 2025, 32% as of September 30, and “38% on a year-to-date basis in 30 days” — Brian Carrico, Chief Executive Officer · 2026-11-09 as of late October. That 6-point month implies a one-month approval rate well above 38%. Management wants that number into the 80s. It is the single cleanest measure of whether IB Stim Category I CPT code adoption and the fee schedule build-out across 27 of 50 states are turning into treated patients.
The mix shift is the actual engine — and the keyword tape says so
Quietly, the most important number in the release is the average selling price: $1,045 per device versus $775 a year ago, as volume flipped from discounted patient assistance to fully reimbursed commercial claims. Two years of keyword history corroborate the flip. large payer was the company's top-ranked theme back in early 2026 — and is now one of its sharpest conceptual decliners, precisely because the two wins landed and the topic stopped being a campaign. financial assistance program has decayed in the same way. Those are the good kind of drop-offs: the narrative moved from aspiration to execution, and the average selling prices line moved with it.
At roughly 20x trailing revenue and an $83 million market cap, the equity is a levered call on the shape of that curve.
Paying for the next leg with a thin balance sheet
The expense guide is the part that changed. Management is adding at least five full-time territories, targeting 10–11 direct salespeople by year-end (12–13 including the senior MSL and strategic clinical directors), launching a targeted digital campaign in October, and running a 1099 VA representative model of ten reps covering one to three hospitals each. The commercial team is being built ahead of the revenue it is meant to harvest — a reversal of the "measure twice, cut once" posture Carrico described in March, when he said he would not hire until a revenue source was visible.
That costs money the company does not have in abundance. Cash stood at $4.5 million at September 30 against a quarterly burn near $1.5 million, with $1.7 million raised through the ATM since quarter-end. The prior 10-Q's effective net cash position of roughly $7 million flattered the picture relative to today's balance. Going concern language remains in the filings, and the CFO was explicit that SG&A and burn rise from here before they fall.
The tape is not arguing with the thesis; it is waiting
The stock is down about 8% over the last 90 days and sits roughly 16% below its October 21 high of $7.92, itself 25% below the May peak of $8.81. That is a market that has heard the coverage story before. In August, an analyst offered congratulations and then added, of the prior quarter's reaction, “hopefully, the market reaction hasn't been favorable” — Unknown Analyst, Analyst · 2026-08-11 — a candid acknowledgment that execution had not yet been rewarded. Nothing in this quarter's price action suggests that changed.
The honest read: NeurAxis now has the coding, the payer contracts, the ASP lift, and a 38% approval rate climbing. What it does not yet have is the 70% state-level coverage density that unlocks hospital-level adoption, and it is spending its thin balance sheet to buy time until it does. The company-unique risk is execution timing — payer policy signed versus prior auth correctly configured versus clinic slots staffed — not demand. That is a far better problem than the one this company had two years ago, and a far easier one for the market to misprice while it stares at a $4.3 million stock-comp line.